Rubicon Research is currently trading at Rs. 832.15, up by 7.60 points or 0.92% from its previous closing of Rs. 824.55 on the BSE.

The scrip opened at Rs. 860.05 and has touched a high and low of Rs. 871.15 and Rs. 829.00 respectively. So far 16532 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 887.95 on 18-Nov-2025 and a 52 week low of Rs. 571.00 on 24-Oct-2025.

Last one week high and low of the scrip stood at Rs. 885.70 and Rs. 813.85 respectively. The current market cap of the company is Rs. 13707.60 crore.

The promoters holding in the company stood at 59.99%, while Institutions and Non-Institutions held 17.43% and 22.58% respectively.

Rubicon Research has entered into definitive agreements to acquire 85% stake in Arinna Lifesciences (Arinna). Upon acquisition, Arinna will become a subsidiary of the Company.

This acquisition furthers Rubicon’s strategy of leveraging its IP and chronic products portfolio to unlock growth in key markets, particularly in the CNS therapeutic category which has always been a core focus area for Rubicon. Arinna’s sales and distribution network will provide Rubicon access to patients and prescribers in India for its differentiated offerings, including a strong pipeline of specialty products and drug-device combinations. 

The acquisition is expected to be completed within one month from the date of the signing of the transaction documents or by such other timelines as may be mutually agreed between the parties. The transaction values Arinna at an enterprise value of Rs 200 crore on a cash and debt free basis. After accounting for necessary adjustments to the enterprise value of Arinna, the purchase consideration has been determined to be approximately Rs 175.92 crore for secondary acquisition of 85% equity shareholding in Arinna on a fully diluted basis at a price of approximately Rs 158.53 per share. The final consideration remains subject to adjustments on the closing date. 

Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of speciality products and drug-device combination products targeting regulated markets and in particular the United States.